Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China To Invest RMB 100 Billion To Equip Grassroots Medical Care Institutions

This article was originally published in PharmAsia News

Executive Summary

Officials from the Department of Planning and Finance under China's Ministry of Health revealed that the country will invest about RMB 100 billion ($14.6 billion) by 2011 to support the development of grassroots medical care institutions. To date, central finance has allocated special subsidies of RMB 20 billion in three batches to fund the construction of 961 county hospitals, 3,556 central healthcare institutes and 1,153 community health service centers. MOH and the National Development and Reform Commission have jointly started the implementation of the grassroots healthcare system improvement program, which will support 2,000 county hospitals, 5,000 central healthcare institutions and 2,400 community health service centers cross the country. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel